menu search

Syfovre® (pegcetacoplan injection) continued to demonstrate increasing treatment effects over 3 years in patients with geographic atrophy (ga)

SYFOVRE reduced nonsubfoveal GA lesion growth by over 40% (monthly) in Year 3 compared to projected sham in the GALE extension ...

November 4, 2023, 5:37 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Elicio therapeutics presents updated preliminary immunogenicity data from the ongoing phase 1 study of eli-002 and new preclinical data on eli-007 and eli-008 at the society for immunotherapy of cance

In patients with high relapse risk mKRAS-driven pancreatic and colorectal cancers who were given ELI-002 2P, an investigational therapeutic cancer vac...

November 3, 2023, 8:30 pm

Sensei biotherapeutics reports favorable clinical data for sns-101 at 2023 sitc annual meeting

– Clinical dose escalation data for SNS-101 monotherapy show well tolerated safety profile, potentially best-in-class pharmacokinetics, and encourag...

November 3, 2023, 8:05 pm

Cerrado gold reports 'very positive' feasibility study results for monte do carmo

(Kitco News) - On Thursday, Cerrado Gold (TSX.V: CERT) (OTCQX: CRDOF) announced “very positive” results of an independent feasibility ...

November 3, 2023, 3:56 pm

Travere therapeutics announces late-breaking data from phase 3 studies of sparsentan in igan and fsgs published in the lancet and the nejm respectively and presented at the american society of nephrol

Two-year results from both PROTECT and DUPLEX pivotal Phase 3 studies demonstrate treatment with sparsentan has the potential to preserve kidney funct...

November 3, 2023, 2:46 pm

Ovid therapeutics reports third quarter 2023 financial results and corporate updates

Received a $30 million payment from Ligand for the sale of a 13% interest in the potential future royalties and milestone payments owed to Ovid for so...

November 3, 2023, 12:00 pm

Gilead to present late breaking data and real world evidence highlighting key hepatitis indications at the liver meeting® 2023

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the presentation of new viral hepatitis data at the America...

November 3, 2023, 11:00 am

Genfit to present update on scientific and corporate progress at the liver meeting® 2023

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 2 2023 - GENFIT (Nasdaq and Euronext: GNFT), a late-stage bio...

November 2, 2023, 5:10 pm

Visa completes pilot test of cbdc in hong kong

Visa, in collaboration with HSBC and Hang Seng Bank, has successfully completed a pilot test in Hong Kong to ...

November 2, 2023, 3:33 pm

Global microfluidics market to touch us$ 23,739.1 million by 2033, registering an 11.9% cagr | fmi study

The microfluidics industry is poised for remarkable growth in the near future, driven by its diverse applications across healthcare, biotechnology, an...

November 2, 2023, 10:30 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Centessa pharmaceuticals to present additional 52-weeks of continuous treatment data from third year of ongoing phase 2a study of serpinpc for the treatment of hemophilia at american society of hemato

BOSTON and LONDON, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Centessa Pharmaceuticals plc (Nasdaq: CNTA) today announced that new data from an additional 52-w...

November 2, 2023, 9:09 am

Agios pharmaceuticals to present broad set of clinical and translational data in rare blood disorders at 65th ash annual meeting and exposition

– Both Mitapivat Dose Arms Achieved Statistically Significant Hemoglobin Response in Phase 2 Portion of RISE UP Pivotal ...

November 2, 2023, 9:05 am

Reviva pharmaceuticals: positive results in phase 3 but the stock is back where it started

Results from the phase 3 RECOVER study of Reviva Pharmaceuticals' antipsychotic brilaroxazine in schizo...

November 2, 2023, 3:11 am

Hillevax to present at upcoming investor conferences

BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- HilleVax, Inc. (Nasdaq: HLVX), a clinical-stage biopharmaceutical company focused on developing and commerci...

November 1, 2023, 4:48 pm

Tourmaline bio: ted and ascvd targeting with differentiated il-6

Tourmaline Bio is advancing the use of its drug candidate TOUR006 for the treatment of thyroid eye disease and atherosclerotic cardiovascular disease....

November 1, 2023, 2:09 pm

Canadian mp urges community to study bitcoin, cites gensler’s pre-sec stance

Gensler, in an opinion piece in 2019, has written that although there Are thousands of projects in the crypto ecosystem, the one created by Satoshi Na...

November 1, 2023, 1:59 pm

Masonic cancer center, university of minnesota to present data in poster presentation human data readout for phase 1 study to evaluate hcw9218 in solid tumors at sitc 38th annual meeting

HCW9218 is the lead product candidate of HCW Biologics Inc. MIRAMAR, Fla., Nov. 01, 2023 (GLOBE NEWSWIRE) — HCW Biologics Inc. (the “Company” or...

November 1, 2023, 11:30 am

Cardiol therapeutics reaches new milestone in phase ii study for recurrent pericarditis

Cardiol Therapeutics (TSX:CRDL, NASDAQ:CRDL) announced it has successfully enrolled over 50% of the targeted number of patients for its Phase II open-...

November 1, 2023, 8:41 am


Search within

Pages Search Results: